Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) Shares Outstanding (Weighted Average): 2020-2025

Historic Shares Outstanding (Weighted Average) for Foghorn Therapeutics (FHTX) over the last 6 years, with Sep 2025 value amounting to $56.5 million.

  • Foghorn Therapeutics' Shares Outstanding (Weighted Average) rose 2.17% to $56.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.5 million, marking a year-over-year increase of 2.17%. This contributed to the annual value of $55.6 million for FY2024, which is 31.68% up from last year.
  • As of Q3 2025, Foghorn Therapeutics' Shares Outstanding (Weighted Average) stood at $56.5 million, which was up 1.41% from $55.7 million recorded in Q2 2025.
  • Over the past 5 years, Foghorn Therapeutics' Shares Outstanding (Weighted Average) peaked at $56.5 million during Q3 2025, and registered a low of $36.8 million during Q1 2021.
  • Its 3-year average for Shares Outstanding (Weighted Average) is $48.3 million, with a median of $42.6 million in 2024.
  • Data for Foghorn Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY soared of 32.17% (in 2024) over the last 5 years.
  • Quarterly analysis of 5 years shows Foghorn Therapeutics' Shares Outstanding (Weighted Average) stood at $37.1 million in 2021, then rose by 12.70% to $41.8 million in 2022, then increased by 0.99% to $42.2 million in 2023, then surged by 31.68% to $55.6 million in 2024, then grew by 2.17% to $56.5 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $56.5 million for Q3 2025, versus $55.7 million for Q2 2025 and $55.6 million for Q1 2025.